• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Amneal Reports Q3 2024 Financial Results

    BUSINESSWIRE

    Amneal Receives FDA Approval For Pyridostigmine Bromide Tablets

    BUSINESSWIRE

    Amneal Expands In India With Two New Manufacturing Facilities

    EXPRESSPHARMA

    Amneal to Report Third Quarter 2024 Results on November 8, 2024

    BUSINESSWIRE

    Amneal And Metsera Partner On Next-Gen Obesity Medicines

    BUSINESSWIRE

    Amneal Launches CREXONT For Parkinson`s Disease Treatment

    BUSINESSWIRE

    Amneal asks court to block Colorado`s free allergy pen program

    REUTERS

    Amneal and Shilpa Announce FDA Approval Of BORUZU, Ready-to-Use

    BUSINESSWIRE

    Amneal Gets FDA Approval For Propofol Injectable Emulsion Single Dose Vials

    BUSINESSWIRE

    Amneal Reports Second Quarter 2024 Financial Results

    BUSINESSWIRE

    Amneal Receives FDA Approval For CREXONT To Treat Parkinson`s Disease

    BUSINESSWIRE

    Amneal Clinches Approval For Extended-Release Parkinson`s Med

    FIERCE PHARMA

    Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

    BUSINESSWIRE

    Amneal to Report Second Quarter 2024 Results on August 9, 2024

    BUSINESSWIRE

    Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

    BUSINESSWIRE

    Amneal`s Generic Calcium Chloride Receives Approval in US

    FDA

    Amneal Adds Omalizumab Biosimilar To Portfolio, Now Eight Products

    BUSINESSWIRE

    Amneal Releases 2023 Environmental, Social and Governance Report

    BUSINESSWIRE

    Amneal’s Early Win Delists Five Teva Orange Book Inhaler Patents

    BLOOMBERGLAW

    Alembic`s Generic Venlafaxine Hydrochloride Receives Approval in US

    FDA

    Amneal`s Generic Azelastine Hydrochloride Receives Approval in US

    FDA

    Amneal: Expands Injectables Portfolio To Over 40 Products

    BUSINESSWIRE

    Amneal Launches OTC Naloxone In US Retail, California

    BUSINESSWIRE

    Amneal to Participate at Upcoming Investor Conference

    BUSINESSWIRE

    Amneal Pharms LLC’s Generic Nimodipine Receives Tentative Approval In US

    FDA

    Drugmaker Amneal agrees to $270 million U.S. opioid settlement

    REUTERS

    Amneal Reports First Quarter 2024 Financial Results

    BUSINESSWIRE

    Amneal`s OTC Naloxone Nasal Spray Approved

    BUSINESSWIRE

    Enforcement Report - Week of April 24, 2024

    FDA

    Amneal Pharm Generic Naloxone Hydrochloride Receives Approval in the U.S.

    FDA

    Amneal appoints Sandeep Raktate as President -Operations, India & Ireland

    EXPRESSPHARMA

    Shilpa Medicare launches Pemetrexed injection

    INDINPHARMAPOST

    Amneal Launches PEMRYDI RTU® Oncology Injectable Ready-To-Use

    BUSINESSWIRE

    Amneal to Report First Quarter 2024 Results on May 3, 2024

    BUSINESSWIRE

    Enforcement Report - Week of April 3, 2024

    FDA

    Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

    BUSINESSWIRE

    Amneal pulls 4 lots of potentially overfilled antibiotic bottles

    FIERCE PHARMA

    Amneal Pharm Generic Lacosamide Receives Approval in the U.S.

    FDA

    Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride

    FDA

    Amneal gains FDA greenlight to develop Ciprodex generic for ear infections

    PHARMACEUTICAL TECHNOLOGY

    Amneal Receives FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

    BUSINESSWIRE

    Enforcement Report - Week of February 28, 2024

    FDA

    Amneal Enters into European Licensing Agreement with Zambon Biotech for IPX203

    PRESS RELEASE

    Enforcement Report - Week of February 14, 2024

    FDA

    Amneal to Participate at Upcoming Investor Conference

    BUSINESSWIRE

    Amneal Announces Complete Response Resubmission for IPX203 New Drug Application

    GLOBENEWSWIRE

    Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024

    BUSINESSWIRE

    Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension

    BUSINESSWIRE

    Amneal`s Generic Fluorometholone Receives Approval in the U.S.

    FDA

    Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023

    BUSINESSWIRE

    Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

    BUSINESSWIRE

    GSK, Amneal and Kaleo walk back patents after FTC`s challenge

    FIERCE PHARMA

    Amneal Announces Move to Nasdaq

    BUSINESSWIRE

    Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

    BUSINESSWIRE

    Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules

    BUSINESSWIRE

    Amneal Reports Third Quarter 2023 Financial Results

    BUSINESSWIRE

    Amneal Pharmaceuticals` Generic Methylprednisolone Acetate Receives Approval in the U.S.

    FDA

    Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results

    BUSINESSWIRE

    Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline

    BUSINESSWIRE

    Amneal to Report Third Quarter 2023 Results on November 7, 2023

    BUSINESSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.